Based on adiponectin-mediated cytotoxic autophagy, we can reasonably hypothesize that adiponectin usage represents a new adjuvant therapy strategy for obese breast cancer patients and that combining adiponectin with chemotherapeutic drugs may therefore reduce the dose of chemotherapeutic drugs (108). The gene discussed is ADIPOQ; the disease is breast cancer.